Abstract：
UNASSIGNED: Despite the considerable progress made in preventative methods, medication, and interventional therapies, it remains evident that cardiovascular events (CVEs) continue to be the primary cause of both death and morbidity among individuals diagnosed with coronary artery disease (CAD).
UNASSIGNED: To compare the connection between lipoprotein a (Lp[a]), fibrinogen (Fib), and both parameters combined with all-cause mortality to detect their value as prognostic biomarkers.
UNASSIGNED: This is a retrospective study. Patients diagnosed with CAD between January 2007 and December 2020 at the Guangdong Provincial People\'s Hospital (China) were involved in the study. 43,367 patients met the eligibility criteria. The Lp(a) and Fib levels were distributed into three tertile groups (low, medium, and high). All of the patients included in the study were followed up for all-cause mortality. Kaplan-Meier and Cox regression were performed to determine the relationship between Lp(a), Fib, and all-cause mortality. A concordance statistics model was developed to detect the impact of Fib and Lp(a) in terms of anticipating poor outcomes in patients with CAD.
UNASSIGNED: Throughout a median follow-up of 67.0 months, 6,883 (15.9%) patients died. Participants with high Lp(a) (above 27.60 mg/dL) levels had a significantly higher risk for all-cause mortality than individuals with low Lp(a) levels (below 11.13 mg/dL; adjusted hazard ratio [aHR] 1.219, 95% confidence interval [CI]: 1.141-1.304, p< 0.001). Similarly, patients with high Fib levels (above 4.32 g/L) had a significantly greater risk of developing all-cause mortality compared with those with reduced Fib levels (below 3.41 g/L; aHR 1.415, 95% CI: 1.323-1.514, p< 0.001). Patients with raised Lp(a) and Fib levels had the maximum risk for all-cause mortality (aHR 1.702; 95% CI: 1.558-1.859, p< 0.001). When considered together, Lp(a) and Fib caused a significant elevation of the concordance statistic by 0.009 (p< 0.05), suggesting a higher value for predicting mortality when combining the two indicators.
UNASSIGNED: High Lp(a) and Fib levels could be used as predictive biomarkers for all-cause mortality in individuals with CAD. The prediction accuracy for all-cause mortality improved after combining the two parameters.
UNASSIGNED: To compare the connection between lipoprotein a (Lp[a]), fibrinogen (Fib), and both parameters combined with all-cause mortality to detect their value as prognostic biomarkers.
UNASSIGNED: This is a retrospective study. Patients diagnosed with CAD between January 2007 and December 2020 at the Guangdong Provincial People\'s Hospital (China) were involved in the study. 43,367 patients met the eligibility criteria. The Lp(a) and Fib levels were distributed into three tertile groups (low, medium, and high). All of the patients included in the study were followed up for all-cause mortality. Kaplan-Meier and Cox regression were performed to determine the relationship between Lp(a), Fib, and all-cause mortality. A concordance statistics model was developed to detect the impact of Fib and Lp(a) in terms of anticipating poor outcomes in patients with CAD.
UNASSIGNED: Throughout a median follow-up of 67.0 months, 6,883 (15.9%) patients died. Participants with high Lp(a) (above 27.60 mg/dL) levels had a significantly higher risk for all-cause mortality than individuals with low Lp(a) levels (below 11.13 mg/dL; adjusted hazard ratio [aHR] 1.219, 95% confidence interval [CI]: 1.141-1.304, p< 0.001). Similarly, patients with high Fib levels (above 4.32 g/L) had a significantly greater risk of developing all-cause mortality compared with those with reduced Fib levels (below 3.41 g/L; aHR 1.415, 95% CI: 1.323-1.514, p< 0.001). Patients with raised Lp(a) and Fib levels had the maximum risk for all-cause mortality (aHR 1.702; 95% CI: 1.558-1.859, p< 0.001). When considered together, Lp(a) and Fib caused a significant elevation of the concordance statistic by 0.009 (p< 0.05), suggesting a higher value for predicting mortality when combining the two indicators.
UNASSIGNED: High Lp(a) and Fib levels could be used as predictive biomarkers for all-cause mortality in individuals with CAD. The prediction accuracy for all-cause mortality improved after combining the two parameters.
摘要：
■尽管在预防方法方面取得了相当大的进展，药物,和介入治疗，在诊断为冠状动脉疾病(CAD)的个体中,心血管事件(CVEs)仍然是死亡和发病的主要原因.
■为了比较脂蛋白a（Lp[a]）之间的联系，纤维蛋白原（Fib），和两个参数与全因死亡率相结合，以检测其作为预后生物标志物的价值。
■这是一项回顾性研究。2007年1月至2020年12月在广东省人民医院（中国）诊断为CAD的患者参与了这项研究。43,367名患者符合资格标准。Lp(a)和Fib水平分为三个三元组(低，中等,和高）。所有纳入研究的患者均接受全因死亡率随访。进行Kaplan-Meier和Cox回归以确定Lp（a）之间的关系，Fib,和全因死亡率。开发了一种一致性统计模型来检测Fib和Lp（a）在预测CAD患者不良预后方面的影响。
■在整个67.0个月的中位随访中，6,883例（15.9%）患者死亡。与低Lp(a)水平(低于11.13mg/dL;校正风险比[aHR]1.219,95%置信区间[CI]:1.141-1.304,p<0.001)相比,高Lp(a)水平(高于27.60mg/dL)的参与者具有明显更高的全因死亡率风险。同样，与Fib水平降低的患者(低于3.41g/L;aHR1.415,95%CI:1.323~1.514,p<0.001)相比,高Fib水平(高于4.32g/L)患者发生全因死亡的风险显著更高.Lp(a)和Fib水平升高的患者具有全因死亡的最大风险(aHR1.702;95%CI:1.558-1.859,p<0.001)。当一起考虑时，Lp(a)和Fib导致一致性统计值显著升高0.009(p<0.05)，提示将这两个指标组合在一起时，死亡率的预测价值更高。
■高Lp（a）和Fib水平可用作冠心病患者全因死亡率的预测生物标志物。综合这两个参数后，全因死亡率的预测精度有所提高。
■为了比较脂蛋白a（Lp[a]）之间的联系，纤维蛋白原（Fib），和两个参数与全因死亡率相结合，以检测其作为预后生物标志物的价值。
■这是一项回顾性研究。2007年1月至2020年12月在广东省人民医院（中国）诊断为CAD的患者参与了这项研究。43,367名患者符合资格标准。Lp(a)和Fib水平分为三个三元组(低，中等,和高）。所有纳入研究的患者均接受全因死亡率随访。进行Kaplan-Meier和Cox回归以确定Lp（a）之间的关系，Fib,和全因死亡率。开发了一种一致性统计模型来检测Fib和Lp（a）在预测CAD患者不良预后方面的影响。
■在整个67.0个月的中位随访中，6,883例（15.9%）患者死亡。与低Lp(a)水平(低于11.13mg/dL;校正风险比[aHR]1.219,95%置信区间[CI]:1.141-1.304,p<0.001)相比,高Lp(a)水平(高于27.60mg/dL)的参与者具有明显更高的全因死亡率风险。同样，与Fib水平降低的患者(低于3.41g/L;aHR1.415,95%CI:1.323~1.514,p<0.001)相比,高Fib水平(高于4.32g/L)患者发生全因死亡的风险显著更高.Lp(a)和Fib水平升高的患者具有全因死亡的最大风险(aHR1.702;95%CI:1.558-1.859,p<0.001)。当一起考虑时，Lp(a)和Fib导致一致性统计值显著升高0.009(p<0.05)，提示将这两个指标组合在一起时，死亡率的预测价值更高。
■高Lp（a）和Fib水平可用作冠心病患者全因死亡率的预测生物标志物。综合这两个参数后，全因死亡率的预测精度有所提高。
